# A Study to Evaluate the Long-term Efficacy and Safety of AK102 in Patients With Hyperlipidemia

Study · id `cardio:ct-nct05255458` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05255458](<https://clinicaltrials.gov/study/NCT05255458>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT05255458

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 122 participants.

## Technical summary

Registry record NCT05255458. Randomized; quadruple masking; primary purpose treatment. Start 2021-11-04 (actual); primary completion 2023-01-09 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 122 participants (enrolled count; ClinicalTrials.gov record NCT05255458, source copy `cardio:ctgov-nct05255458-2025-02-28`, retrieved 2026-10-31)
- Started: 2021-11-04 (actual) (ClinicalTrials.gov record NCT05255458, source copy `cardio:ctgov-nct05255458-2025-02-28`, retrieved 2026-10-31)
- Primary completion: 2023-01-09 (actual) (ClinicalTrials.gov record NCT05255458, source copy `cardio:ctgov-nct05255458-2025-02-28`, retrieved 2026-10-31)
- Completion: 2023-01-09 (actual) (ClinicalTrials.gov record NCT05255458, source copy `cardio:ctgov-nct05255458-2025-02-28`, retrieved 2026-10-31)
- Countries: China (ClinicalTrials.gov record NCT05255458, source copy `cardio:ctgov-nct05255458-2025-02-28`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05255458-2025-02-28`, retrieved 2026-10-31)

## The registry's words

- Brief title: A Study to Evaluate the Long-term Efficacy and Safety of AK102 in Patients With Hyperlipidemia
- Condition: Hyperlipidemia
- Intervention (Biological): AK102
- Intervention (Drug): Placebo
- Lead sponsor: Akeso
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry lists this organization as the lead sponsor: Akeso (`cardio:org-akeso`)

## Provenance

Content hash: 756b85a792fc531e14a7175722c6cef0bf217f5d34131caa7ffd772491a92bf9
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
